Headquartered in Wayne, PA Fiscal year ends December NYSE: TFX teleflex.com
Teleflex Incorporated is a global medical technology company. It provides single-use and disposable devices for anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access and urology.
Since the third quarter of 2026, continuing operations are reported in three global business units:
- **Vascular:** intraosseous, vascular access, hemostatic and peripheral access products.
- **Interventional:** complex and right heart catheters, OnControl, hemostatic products, and the Vascular Intervention business acquired from BIOTRONIK.
- **Surgical:** ligation clips, skin staplers and surgical instruments.
Teleflex is transforming its portfolio. It sold its OEM business for $1.5 billion in August 2026 and is pending a sale of its Acute Care and Interventional Urology businesses to Intersurgical; those businesses are reported as discontinued operations. Growth initiatives include EZPLAZ, an FDA-licensed freeze-dried plasma aimed initially at the U.S. government and military, and Freesolve, a resorbable magnesium scaffold in clinical trials. Its brands include Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck. Updated
A $16.5 million refund of IEEPA tariffs, freed up by the Supreme Court ruling that voided those levies, powered a 39% earnings beat at Teleflex. Management raised full-year adjusted EPS guidance to $7.50 to $7.75 and is still targeting a year-end close on the Acute Care and Interventional Urology sale.
A $16.5 million refund of IEEPA tariffs, freed up by the Supreme Court ruling that voided those levies, powered a 39% earnings beat at Teleflex. Management raised full-year adjusted EPS guidance to $7.50 to $7.75 and is still targeting a year-end close on the Acute Care and Interventional Urology sale.
A $16.5 million refund of IEEPA tariffs, freed up by the Supreme Court ruling that voided those levies, powered a 39% earnings beat at Teleflex. Management raised full-year adjusted EPS guidance to $7.50 to $7.75 and is still targeting a year-end close on the Acute Care and Interventional Urology sale.
Pre-Market Stock Futures: Futures are trading lower as we enter the final trading days of the third quarter, after a wild week in which interest rates soared and oil prices bounced back…
Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, and, as we mentioned before, it all depends on the status of the war with Iran and…
Teleflex Incorporated is a global medical technology company. It provides single-use and disposable devices for anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access and urology.
24/7 Wall St.'s 12-month price target for TFX is $189.45, rated Buy. The Wall Street consensus target is $154.00. TFX price prediction →
